82611-65-2

Usage

Uses

Used in Pharmaceutical Drug Production:
N-Carbobenzyloxy-S-phenyl-L-cysteine is used as a key intermediate in the synthesis of pharmaceutical drugs, contributing to the development of new therapeutic agents.
Used in Peptide Synthesis:
In the field of peptide chemistry, N-Carbobenzyloxy-S-phenyl-L-cysteine is used as a building block for creating peptides. Its protected carboxyl group facilitates controlled peptide synthesis, allowing for the stepwise assembly of complex peptide structures.
Used in Peptide Modification:
N-Carbobenzyloxy-S-phenyl-L-cysteine is utilized for the modification of peptides, enabling the introduction of specific functional groups or structural elements that can alter the properties or activities of the peptide.
Used in Research and Development:
In the study of peptide chemistry and biology, N-Carbobenzyloxy-S-phenyl-L-cysteine serves as a valuable tool for investigating the structure-function relationships of peptides and for exploring their potential applications in various biological processes and therapeutic interventions.

Upstream product

• 34317-61-8 S-phenyl-L-cysteine 
• 501-53-1 benzyl chloroformate 
• 153277-33-9 N-benzyloxycarbonyl-S-phenyl-L-cysteine methyl ester 
• 26054-60-4 ((S)-2-Oxo-oxetan-3-yl)-carbamic acid benzyl ester 
• 108-98-5 thiophenol 
• 1145-80-8 N-(benzyloxycarbonyl)-L-serine 
• 67-68-5 dimethyl sulfoxide 
• 108-86-1 bromobenzene 
• 12775-96-1 copper 
• 6968-11-2 N,N'-bis-benzyloxycarbonylcystine 
• 7625-65-2 L-carbobenzyloxy-β-chloroalanine 
• 132249-34-4 Methyl (S)-2-benzyloxycarbonylamino-3-methylsulfonyloxypropanoate 
• 930-69-8 sodium thiophenolate 
• 1676-81-9 N-benzyloxycarbonyl-L-serine methyl ester 

Downstream Products

• 123201-59-2 N-(benzyloxycarbonyl)-S-phenyl-L-cysteinyl-D-valine methyl ester 
• 153277-34-0 (R)-2-Benzyloxycarbonylamino-1-(tert-butyldimethylsilyloxy)-3-phenylthiopropane 
• 153379-64-7 O-Deacetyl-N-(benzyloxycarbonyl)slaframine 
• 153277-29-3 ((1S,6S,8aS)-1-Methoxymethoxy-octahydro-indolizin-6-yl)-carbamic acid benzyl ester 
• 153379-66-9 (1S,6S,8aS)-6-(benzyloxycarbonylamino)octahydroindolizin-1-yl acetate 
• 153277-21-5 (R)-2-Benzyloxycarbonylamino-1-(tert-butyldimethylsilyloxy)-3-phenylsulfonylpropane 
• 153277-31-7 (2S,3S)-2-((S)-3-Benzyloxycarbonylamino-4-hydroxy-butyl)-3-methoxymethoxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 153277-32-8 (2S,3S)-2-((S)-3-Benzyloxycarbonylamino-4-methanesulfonyloxy-butyl)-3-methoxymethoxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 21149-17-7 methyl 2-(benzyloxycarbonylamino)acrylate 
• 159878-02-1 benzyl [(2R,3S)-4-chloro-3-hydroxy-1-(phenylsulfanyl)-2-butanyl]carbamate 
• 1315549-68-8 (S)-benzyl N-(chroman-3-yl)carbamate 

Relevant academic research and scientific papers

Method of making HIV protease inhibitors

A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Process for S-Aryl cysteine

The present invention provides methods for preparing S-aryl cysteines in enantiomeric excess of greater than about 96%. Specifically, the present invention provides enantioselective methods for preparing S-aryl cysteines starting from cystine, cysteine or

Processes for producing β-halogeno-α-amino-carboxylic acids and phenylcysteine derivatives and intermediates thereof

An industrially advantageous method of producing β-halogeno-α-aminocarboxylic acids is provided. Methods are also provided of producing optically active N-protected-S-phenylcysteines having high optical purity and of intermediates thereof, respectively, in which the above production method is utilized. A method of producing β-halogeno-α-aminocarboxylic acids or salts thereof is disclosed which comprises halogenating the hydroxyl group of a β-hydroxy-α-aminocarboxylic acid (in which the basicity of the amino group in α-position is not masked by the presence of a substituent on said amino group) or a salt thereof with an acid with a halogenating agent. A method of producing optically active N-protected-S-phenylcysteines represented by the general formula (3) or salts thereof is further disclosed which comprises applying the above production method to optically active serine or a salt thereof and then carrying out treatment with an amino-protecting agent and reaction with thiophenol under a basic condition.

Preparation of S-aryl-cysteine and its derivatives

The present invention provides a method for preparing S-aryl cysteine. Specifically, the present invention provides enantioselective method for preparing S-aryl cysteine starting from cystine, cysteine or serine amino acid. The methods of the present inve

Method for isolation of n-protected s-phenylcysteine

This invention provides a method of isolating N-protected-S-phenylcysteine (1) of high purity, expediently, efficiently and in good yield, which comprises causing said N-protected-S-phenylcysteine to be salted out in the form of a base salt in the presence of water. wherein R1represents an amino-protecting group; R2represents a hydrogen atom or, either independently of R1or taken together with R1, represents an amino-protecting group.

Copper-mediated cross-coupling of aryl boronic acids and alkyl thiols

matrix presented The cross-coupling of aryl boronic acids and alkanethiols mediated by copper(II) acetate and pyridine in anhydrous dimethylformamide affords aryl alkyl sulfides in good yield with a wide variety of substituted aryl boronic acids. The method is applicable to the synthesis of aryl sulfides of cysteine.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease

Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain the